Transcriptomics

Dataset Information

0

A phase I trial of the IL1-receptor antagonist anakinra in previously untreated CLL patients at risk for progression


ABSTRACT: Inflammatory factors that activate NFkB play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL) but are not addressed specifically by current therapies. Interleukin-1 (IL-1) is a master-regulator of inflammation that is inhibited safely in humans by the IL-1 receptor antagonist anakinra. Anakinra was found to inhibit NFkB activity in CLL cells in an IL-1 receptor independent manner and had properties of an intracellular anti-oxidant in vitro. A phase I dose-escalation trial in 11 previously untreated CLL patients (NCT04691765) indicated anakinra was safe at doses up to 400 mg daily and produced transient clinical responses associated with down-regulation of NFkB and oxidative stress in circulating CLL cells in vivo. However, type 1 interferon (IFN)-signaling and c-MYC-regulated genes and proteins were induced at the same time.

ORGANISM(S): Homo sapiens

PROVIDER: GSE236606 | GEO | 2023/10/04

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-10-04 | GSE236552 | GEO
| PRJNA991645 | ENA
2021-11-27 | GSE188809 | GEO
2009-12-31 | GSE17590 | GEO
2013-12-10 | E-MTAB-1567 | biostudies-arrayexpress
2017-04-09 | GSE80446 | GEO
2014-10-06 | E-GEOD-55288 | biostudies-arrayexpress
2021-07-28 | GSE174638 | GEO
2015-10-01 | GSE37025 | GEO
2020-02-14 | GSE141072 | GEO